clinical trial · NCT07512427
Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants
MASHOPK-88006Placebo
brief summary
Two-part Phase 1/2 study of OPK-88006, including an open-label SAD phase in healthy participants and a double-blind, randomized, placebo-controlled MAD phase in participants with presumed MASH, to evaluate safety, PK, and MASH related pharmacodynamic changes compared to placebo.
started
Dec 1, 2026
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Apr 6, 2026
official title
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of OPK-88006 in Healthy and Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol